Holen Sie sich die Stockscreener-App
5.09
0.32%
0.04
Schlusskurs vom Vortag:
$5.13
Offen:
$4.88
24-Stunden-Volumen:
65,501
Relative Volume:
0.03
Marktkapitalisierung:
$7.60M
Einnahmen:
$8.62M
Nettoeinkommen (Verlust:
$-6.15M
KGV:
-0.4615
EPS:
-11.03
Netto-Cashflow:
$-5.32M
1W Leistung:
-26.37%
1M Leistung:
+74.79%
6M Leistung:
+15.39%
1J Leistung:
-24.89%
1-Tages-Spanne:
$4.8467
$5.2984
1-Wochen-Bereich:
$4.8467
$6.79
52-Wochen-Spanne:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Firmenname
Evoke Pharma Inc
Sektor
Telefon
858-345-1494
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Vergleichen Sie EVOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
5.09 | 3.97M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
151.03 | 70.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.64 | 47.44B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.685 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.85 | 19.07B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.01 | 13.28B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | Fortgesetzt | FBR & Co. | Buy |
| 2017-03-16 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-01-30 | Hochstufung | Laidlaw | Neutral → Buy |
| 2017-01-05 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | Bestätigt | Rodman & Renshaw | Neutral |
| 2016-07-19 | Bestätigt | FBR Capital | Outperform |
| 2016-07-19 | Herabstufung | Noble Financial | Buy → Hold |
| 2016-07-18 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | Eingeleitet | Northland Capital | Outperform |
| 2016-03-14 | Bestätigt | Ascendiant Capital Markets | Buy |
| 2016-02-17 | Fortgesetzt | FBR Capital | Outperform |
| 2014-12-03 | Bestätigt | MLV & Co | Buy |
| 2014-11-07 | Eingeleitet | MLV & Co | Buy |
| 2014-04-22 | Eingeleitet | Laidlaw | Buy |
| 2013-11-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Evoke Pharma Inc. stock price move sharplyVerified Chart Patterns - Newser
How Evoke Pharma Inc. stock performs during market volatilityFree Real-Time Stock Data - Newser
Small Cap Stocks Worth Watching – July 9th - Defense World
Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - Asianet Newsable
Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest
Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener
Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade
EVOK Stock: Boom or Bust? - timothysykes.com
Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus
Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com Nigeria
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com
Evoke Pharma (EVOK) Secures Key Patent for Gastroparesis Treatment | EVOK Stock News - GuruFocus
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | EVOK Stock News - GuruFocus
Evoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in Treatment of Gastroparesis Symptoms - Quiver Quantitative
Evoke Pharma Receives Notice of Allowance for U.S. Patent - GlobeNewswire
Major Patent Win: GIMOTI Locks Down 6 More Years of Exclusivity for Revolutionary Gastroparesis Spray - Stock Titan
Evoke Pharma Secures Patent for GIMOTI Treatment - TipRanks
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Evoke Pharma (NASDAQ:EVOK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance
Gastroparesis Treatment Market Booming Worldwide with - openPR.com
Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com
Geriatric Medicines Market Expands Globally with Aging - openPR.com
Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com
Global Geriatric Medicines Market Generated Opportunities, - openPR.com
Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com
Evoke Pharma Holds Annual Meeting via Webcast - TipRanks
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World
Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
7.87%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):